The Cost-Effectiveness of Efgartigimod Alfa (Vyvgart) in the Treatment of Myasthenia Gravis: An Insight

By Staff Writer

December 18, 2023

 The Purpose and Pricing of Efgartigimod Alfa

Efgartigimod Alfa, a drug designed to ameliorate symptoms of Generalised Myasthenia Gravis (gMG), has been reimbursed since April 2023 in Japan. The drug is priced at JPY 421,455 for Vyvgart® for intravenous infusion 400 mg as of September 2023. Center for Outcomes Research and Economic Evaluation for Health (C2H) calculate the price using a model for the Efgartigimod Alfa Cost-effectiveness. They then add a 5% usefulness premium and a 10% market premium. 

The Scope of the Efgartigimod Alfa Cost-effectiveness

The cost-effectiveness evaluation of Efgartigimod alfa targets two populations: acetylcholine receptor antibody-positive and antibody-negative patients. The comparators were prednisolone ± immunosuppressive drug ± acetylcholinesterase inhibitor.

Evaluation of Additional Benefits

The manufacturer did not conduct a systematic review in the base case analysis but evaluated the additional benefits of Efgartigimod alfa for patients with gMG as a whole. The academic group decided to evaluate based on scope. They assessed additional benefits for each population using the ADAPT trial. 

Results of the Cost-effectiveness Analysis

The manufacturer conducted a cost-utility analysis using a Markov model, which had states of Efgartigimod alfa or the comparator as first-line treatments, intravenous immunoglobulin or plasma exchange as second-line treatments, eculizumab as third-line treatment (only for population [a]), and the best supportive care.

The Expert Committee of Cost-Effectiveness Evaluation accepted the following:

Reference url

Recent Posts

Sword Health mental health
         

How Does Mind’s AI-Driven Mental Healthcare Transform Care?

🤔 Are we ready to embrace AI in mental health care?

Sword Health has just secured €34.6 million to launch **Mind**, an innovative AI-powered mental health solution, blending licensed clinicians with continuous monitoring through wearables. This strategic expansion aims to address the pressing global mental health crisis while promoting personalized and proactive care models. 🌍🧠

Dive into how Sword Health is revolutionizing healthcare and bridging the gap between technology and clinical expertise.

#SyenzaNews #HealthTech #AIinHealthcare #DigitalTransformation

transparency in industry partnerships
   

Transparency in Industry Partnerships: Building Trust

🔍 How does transparency in industry partnerships impact patient care?

In the evolving landscape of healthcare, EFPIA’s mandatory disclosure requirements for financial interactions underscore the vital role of transparency in fostering trust and collaboration. By detailing financial transfers to healthcare professionals and organizations, the European Disclosure Gateway facilitates informed decision-making and strengthens relationships between stakeholders.

Have a look at the article to explore how these initiatives not only enhance public confidence but also drive innovation in treatments!

#SyenzaNews #HealthcareInnovation #HealthEconomics #innovation

DALY modeling methods
        

DALY Modeling Methods for Enhanced Health Economics and Policy Analysis

How can DALY modeling methods revolutionize health policy and decision analysis? 🔍

DALY modeling techniques provide vital insights into disease burden, helping policymakers and analysts make informed, evidence-based decisions about resource allocation. This article breaks down the latest advancements in DALY modeling, ensuring you grasp the methodologies that can enhance health economics practices.

Don’t miss out on learning how these robust methods can shape better health outcomes. Dive into the full article for all the essential details!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.